¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/6/6 ¤W¤È 11:24:34
²Ä 183 ½g¦^À³
|
ARQL - ArQule, Inc. ¤w¸gº¦¨ì5.5¬ü¤¸¡A·à¤l¬ü°êADR¦¬9.9¬ü¤¸¡A³Ì°ª´¿¬ð¯}10.4¬ü¤¸¡A¥Ø«e¨S¦³¦P¨B¤ÏÀ³¤£¥Î¾á¤ß¡A¥ý¤í±b¡A¤]ÅýÁÙ¨S¤W¨®ªºª©¤Í¦³±q®e¤W¨®ªº¾÷·|¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2018/6/6 ¤W¤È 09:22:08
²Ä 182 ½g¦^À³
|
¨È·à±d³Ìªñº¦´T¨S¦h¤Ö¡A³ºµM³Q¦C¬°Äµ¥ÜªÑ¡A¬ÝµÛADR¤@ª½¤W½Ä¡A²{¦b¥xÆW³oÃäªÑ»ù·|¨ü¨ì¤À½L¥æ©ö¼vÅT¡A¬Ý¨Ó·|³QÀ£½L¦n¤@°}¤l¤F¡A¯uªº«Ü¥i±¤¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/6/6 ¤W¤È 09:18:28
²Ä 181 ½g¦^À³
|
ÁÂÁ¤ѩR¤j³o°}¤lªº±K¤Á°lÂܤΤÀªR~~ªº½T!!ªø½u»ùÈ¥ÑÁ{§É¼Æ¾Úªº¥æ¤e¤ñ¹ï«áªº¦bªvÀøPan-Her+ªº¼ç¤O¤ÎADR/¥xÆWªÑ»ùªº»ù®t´N¥i¥Hª¾¹D~
¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X°Ñ¦Ò¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/6/6 ¤W¤È 08:29:39
²Ä 180 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j~
¬OU3-1401ÁÙ¬OU3-1402? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/6/1 ¤U¤È 10:44:56
²Ä 179 ½g¦^À³
|
¦Ñ·à¨üÁÜ°Ñ¥[6/7·ç¤h«H¶U¥D¿ì¤§Greater China Healthcare Corporate Day-ªk»¡·|³ø§i¦p¤U³sµ²:
¤×¨ä¬O²Ä6¤Î13~14¶-GÀù¼ç¦b¯f±w¼Æ(¤ñÁx¹DÀù§ó¦h)¤Î¤G´Á¼Æ¾Ú±N©ó2H18´¦ÅS~ªø½u»ùȤ@¤@¯B²{
mops.twse.com.tw/nas/STR/649720180531M001.pdf
¥H¤W¨Ñ°Ñ¦Ò,¤Å·íªÑ²¼¶i¥X¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/6/1 ¤U¤È 10:21:07
²Ä 178 ½g¦^À³
|
ASLAN PHARMACEUTICALS LIMITED 106¦~¦~³ø¥XÄl 37--50 Àç¹B·§ªp
mops.twse.com.tw/mops/web/t57sb01_q5 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/6/1 ¤W¤È 12:10:25
²Ä 177 ½g¦^À³
|
¨È·à±d-KY¬O¤@°¦¨È¬w·à ¤j³¡¤ÀªºªÑÅv³£¦b¥xÆWÂd¶R¥æ©ö ¬ü°êADR¥u¬O¤@¤p³¡¤À §Ú¤]´¿¸gÃö¤ß¹L·à¤l¬ü°êADRªºªí²{ ¦ý«á¨Ó·Q³q¤F ¥xÆWªÑ»ù¤~¬O¼Ð¬ñ ¥~°ê¤H¶R½æ¥x¿n¹qªºADR¤]¬O°Ñ¦Ò¥xÆWªºªÑ»ù ³»¦h¦A¥[¤W¬üªÑÁ`¸gªºªí²{ ©Ò¥H¤£¥Î¦b¥GADRªºªí²{ ¤§«eºâ¹L§â©Ò¦³¨È·à±d-KYªºADR¶R¤U¥u»Ý¥x¹ô10»õ ¦pªG¦³¤H¶R¤U¤@¥bªºADRªÑÅv ¤µ¤ÑÅý¥L¤Wº¦30% ©ú¤ÑÅý¥L¤U¶^30% ¯u¬O©ö¦p¤Ï´x |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkenken10138351 |
µoªí®É¶¡:2018/5/31 ¤U¤È 01:55:02
²Ä 176 ½g¦^À³
|
½æ¤Ó¦¤FÂI¡AÂê¤F§Ö¤@¸U±i¡A¨º¨Ç¥h¶RADRªº¤H¡A¥i¤£¬OµL½tµL¬G¥h¶R¡A³£¬O°Ñ¦Ò³o¨Ç³ø§iªº¡Aı±o»{¦P¤~·|¶R¡A³o¨Ç³ø§i³£nªá¿ú¶R¡A¤@¯ë´²¤á¬Ý¤£¨ì¡A¥u¦³°òª÷¸g²z¤H©Î¬O¦³¥I¶Oªº«È¤á¤~¦³¡A©Ò¥H¥hgoogle·íµM§ä¤£¨ì¡C³Ì«áÁÙ¬O¬°±z¥i±¤¤F¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/31 ¤U¤È 12:28:45
²Ä 175 ½g¦^À³
|
§Ú¤µ¦¤w½æ¤@¥b·à¤l«ùªÑ ¦]¬°·j´M¤£¨ì¥ô¦ó¹ê½è§Q¦h ¥u¦³´CÅé³Û»ù½Õ°ª¥Ø¼Ð»ù ¤H¬°ª£§@¦¨¥÷©~¦h ¤µ¤Ñ¤S³{¤ë©³¥~¸ê§@±b «ç»ò¤W¥h´N«ç»ò¤U¨Ó ¦pªG©ú¤Ñ¦¤WADR³Q¥´¦^ì§Î ¤£´NGG¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/31 ¤W¤È 08:49:29
²Ä 174 ½g¦^À³
|
«z~~¤j®a³£¦^¨Ó¤F,¬Ý¨Ó¥«È·|¨ì¦h¤Ö¤j®a¤ß¸Ì³£¦³ÃФF~~Ä~Äò¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/31 ¤W¤È 08:31:40
²Ä 173 ½g¦^À³
|
ÁÂÁ²q·Q¤j¤jªº¹ªÀy¡A´Á¬ß¦³¼ç¤Oªº¥Í§Þ¤½¥q³£¯àÀò±oÀ³¸Ó¦³ªº»ùÈ¡AÅwªï¤@°_¬ã¨sµo±¸¦³¼ç¤Oªº¥Í§Þ¤½¥q¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GKO10139074 |
µoªí®É¶¡:2018/5/31 ¤W¤È 08:08:23
²Ä 172 ½g¦^À³
|
¦hÁÂ¥xÁÞ¤j¤Î²³¤jªº¤À¨É ±µµÛ´N¬OASCO¦~·|µoªí¡A¬Ý¨Ó³vº¥¬Ý¨ìÀÆ¥ú¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G²q·Q10136148 |
µoªí®É¶¡:2018/5/31 ¤W¤È 06:29:58
²Ä 171 ½g¦^À³
|
¥xÁÞ¤j¤j ·à¤ÍÌ ®¥³ß¤F ¥XÀY¤Ñ¤F finance.yahoo.com/quote/ASLN/ ASLAN Pharmaceuticals Limited (ASLN) NasdaqGM - NasdaqGM Real Time Price. Currency in USD
9.21+2.36 (+34.45%) At close: 4:00PM EDT 9.10 -0.11 (-1.19%)66 After hours: 5:50PM EDT
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/30 ¤U¤È 11:40:38
²Ä 170 ½g¦^À³
|
¦nªÑ¤£·|±I¹æ ¤Ñ©R¤j ÁÂÁ Åwªï¤@°_¬ã¨s·à¤l
ÁÂÁÂKenken ¤j´£¨Ñ´^³ÕªÀ³Ì·s¸ê°T ( ¤j´T½Õ°ª Asln ADR ¥Ø¼Ð»ù)
www.marketwatch.com/investing/stock/asln
±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O
1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ60% - 70% 2 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³¤½§i¤¤°êÁ{§É¸ÕÅç¼Æ¾Ú 2019¦~²Ä¤@©u ¤½§i¥þ²y¼Ï¯Ã¸ÕÅç¼Æ¾Ú,
3¨È·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q,¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q 4 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O ( ÁÙ¦³«æ©Ê°©Åè©Ê¥Õ¦å¯f¤G´Á¼Æ¾Ú GÀù¤G´Á¼Æ¾Ú ¤]±N¦b¤U¥b¦~¤½§i ) 5 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,¦³¦nªº¼Æ¾Ú¤~¦³¦nªºADR »ù®æ ,¤]¤~¦³¦nªº±ÂÅv©Î¨ÖÁÊ»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g ¶O¤£¯Ê ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò ,½Ð¤Å·í¨Ì¾Ú¬°§ë¸ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkenken10138351 |
µoªí®É¶¡:2018/5/30 ¤U¤È 11:17:09
²Ä 169 ½g¦^À³
|
(Bloomberg) -- BTIG LLC initiated coverage of Aslan Pharmaceuticals Ltd.¡¦s American depository receipts with a recommendation of buy.
PT set to $16, implies 134% increase from last close. Aslan Pharmaceuticals average PT is $14.50
Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) received a Buy rating and a $12 price target from H.C. Wainwright analyst Ram Selvaraju today. The company¡¦s shares closed yesterday at $6.85, close to its 52-week high of $6.94. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkenken10138351 |
µoªí®É¶¡:2018/5/30 ¤U¤È 11:12:17
²Ä 168 ½g¦^À³
|
(Bloomberg) -- Leerink Partners LLC initiated coverage of Aslan Pharmaceuticals Ltd.¡¦s American depository receipts with a recommendation of market perform.
PT set to $7, implies 2.2% increase from last close. Aslan Pharmaceuticals average PT is $12
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2018/5/30 ¤U¤È 02:53:37
²Ä 167 ½g¦^À³
|
³o¨â¤Ñ·Pı¬O¥xÆWº¦±a°ÊADRº¦¡A¤µ¤Ñ¥xÆW³oÃä¤S¨ü¨ìADRªº¼vÅTÄ~Äò©¹¤W½Ä¡A¤£¹L¥Ø«e·Pı¥xÆW³oÃ䪺§ë¸ê¤H¤ñ¸û¬Ý¦n¡A¦³¦n´X¤Ñ³£¬OADR¶^¡A¦ý¬O¥xÆW³oÃ亦¡AÁÙ¬O§Æ±æ»°§Ö¨È·à±d¯àºÝ¥X¤@¨Ç¦¨ªG¡AÅýADR±a°Ê¥xÆWªºªÑ»ù©¹¤W½Ä! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GRock10135634 |
µoªí®É¶¡:2018/5/30 ¤W¤È 09:52:12
²Ä 166 ½g¦^À³
|
¬Q¤Ñ¥xªÑ¥ý©Ô§À½Lº¦°± ±µµÛ±ß¤WADR´N¤jº¦¤F¡A¤]¨S¦³¥ô¦ó®ø®§µo§G |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/30 ¤W¤È 08:31:15
²Ä 165 ½g¦^À³
|
¦³¤Hª¾¹D¨È·à±d¬ü°êADR¬°¦ó¤jº¦? finance.yahoo.com/quote/ASLN?ltr=1
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gª£¦Ì¯»10146792 |
µoªí®É¶¡:2018/5/29 ¤W¤È 11:09:44
²Ä 164 ½g¦^À³
|
¤§«e¨â¦ì§ëÅU¬Oµ¹¤©¤¿ªºµû»ù¡A¦ý¨Æ»PÄ@¹H¡A«á¨ÓºG¶^¡Aarql¤Ï¦Ó¥û²rªºº¦¤W¥h¡A©Î³\¬O¦Ñ·àªºµL¤j¼tÀ°§U¾P°âºÞ¹D¯à§_²£¥Í»ùȳQ½èºÃ§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/29 ¤W¤È 09:27:33
²Ä 163 ½g¦^À³
|
¥Ø«eARQL(»P¦Ñ·àªºÃĦPÄÝÁxÀù½d³ò,·Ó²Î¤@ÃÒ¨éµû¦ô¦Ñ·àÁ{§É¶i«×À³·|¤ñ¥L§Ö)¦b¬ü°ê¥«È¤w¹F5.60»õ¬ü¤¸,Y¬O¦p¦¹¦Ñ®vªº¥«ÈÀ³¸Ó¦h¤Ö¤~¦X²z?¤£ª¾¦U¦ì¤j¤j¦³µL°ª¨£¥i¨Ñ¤À¨É ? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/23 ¤U¤È 11:38:08
²Ä 162 ½g¦^À³
|
©t¨àÃĤj¨£¸Ñ¿W¨ì ©ú¹î¬î²@ ¨È·à±d ¦b 2018 06 03 ASCO µoªíªº¨ÅÀùºKn¤w»¡ªº«Ü²M·¡¤F ,·|¬ã¨sÁp¦X¥ÎÃÄ: Varlitinib + ¶PÀù¥ + P ¤]´N¬O V + T + P
¯E¹© ·à¤l¤µ¦~¶Ò¸ê§¹¦¨ ±N¦¨¬°°ê¤º¨â®a²{ª÷»È¼u¥R¨¬ªº¥Í§Þ¤½¥q, ±ÂÅv»P¨ÖÁʽͧPÄw½X¤j¼W, ¯E¹©¥H¤T³±©Ê¨ÅÀù¬°¹ï¶H»P·à¤l¥HHER2+¨ÅÀù ¬°¹ï¶H ( ¤£½Ä¬ð )
¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú
¨È·à±dªÑ¥÷¦³¤½¥q2018¦~ªÑªF±`·| 2017 ¦~«×Àç·~³ø§i®Ñ ( Á{§É³¡¤À) ( ¸ê°T¨Ó·½: ¤½¶}¸ê°TÆ[´ú¯¸)
¦U¦ìªÑªF¤k¤h¡B¥ý¥Í: ¨È·à±d¦b 2017 ¦~¨ú±o«¤j¶i®i¡A¶¶§Q¦¨¬°°Ó·~¤Æ¶¥¬qªº¥Í§Þ¤½¥q¡A¥»¤½¥q¥Ø«e¦@¦³¤T¶µ¼Ï¯ÃÁ{ §É¸ÕÅ祿¦b¶i¦æ¤¤¡A¨Ã©óªñ´Á«Å¥¬¨ä¤¤¶i®i³Ì§Ö¡B©ó¤¤°ê¤j³°¶i¦æ¤§¸ÕÅç¶i«×¶W¥G¥ý«e¹w´Á¡A¹w p¥i´£«e¦b 2018 ¦~©³¶i¦æ¼Æ¾Ú¤ÀªR¡C¬°¦]À³¤W¥«¶i«×´£«e¡A¥»¤½¥q¤wµÛ¤â¦b¤¤°ê¤j³°¦¨¥ß¾P°â ³¡ªù¡A¤¤°ê¤j³°¹wp±N¦¨¬°¥»¤½¥q²Ä¤@ÓÃĪ«¤W¥«ªº¥«³õ¡A¤é«á¥ç·|±N¨B¤J§¹¦¨¶¥¬q¤§¥þ²y©Ê¼Ï ¯Ã¸ÕÅç¡A©Ý®i¦Ü¬ü°ê¥«³õ¡C¨È·à±d¤µ¦~»P Array Ãļt«·sñq±ÂÅv¦X¬ù¡A¨ú¥Nì©ó 2011 ¦~ñq¤§ ¦X¬ù¤º®e¡A¦V Array Ãļt¨ú±o¨È·à±d¥DnÔ¿ïÃĪ« varlitinib ªº¥þ²y°Ó·~¤Æ©Ò¦³Åv¡A¬°¤é«á¤½¥q°Ó ·~¤ÆÂ૬³þ©w°ò¦¡C¥»¤½¥q¥ç©ó¤µ¦~©e¥ô Stephen Doyle ¾á¥ô¨È·à±d¤¤°êÁ`¸g²zº[°Ó°È°ÆÁ`µô¡A Doyle ¥ý¥Í´¿¾á¥ô°ê»Úª¾¦WÃļt Sanofi (ÁÉ¿Õµá) »P Boehringer Ingelheim (¦ÊÆF¨Î®ï®æ¿«) ¦b¤¤°ê¤j ³°ªº¸~½F³¡ªùt³d¤H¡A¨Ã±À°Ê¹L¦h¶µ·sÃĤW¥«¡A¥¼¨Ó¥ç±N¨ó§U±À°Ê varlitinib ©ó¤¤°ê¤j³°¤W¥«¤§¬Û Ãöpµe¡C ¨È·à±d¤]¦b¨ä¥L²£«~¶µ¥Ø¤W¨ú±o¶i®i¡A¥H½T«O²£«~²Õ¦Xªº¶}µo·ÀI¥¿Å¡AASLAN003 °w¹ï«æ©Ê°©Åè ©Ê¥Õ¦å¯f¬ã¨s¤w¶i¤J¤G´Á¡A¦Ó ASLAN004 ±N¶i®i¦Ü¥Ó½ÐÁ{§É¸ÕÅç¼f¬d (IND) ©Ò»Ý¤§¬r²z©Ê¸ÕÅç¡C ¬°¤ä«ù¥H¤W·s¸ÕÅ窺«ùÄò¶i¦æ¡A¨È·à±d©ó 2017 ¦~ 6 ¤ë 1 ¤é¦bÃÒú³ÂdÂi¶R½æ¤¤¤ß§¹¦¨º¦¸¤½¶}µo ¦æ¡A¶Ò±o·s»O¹ô 10 »õ¤¸¤§¸êª÷¡A¦¨¬°²Ä¤@®a¦b»OÆW±¾µP¤WÂdªº¥~°ê¥Í§Þ¤½¥q¡C¹L¥h¤@¦~ªÑ²¼¥«³õ ªi°Ê°_¥ñ¸û¤j¡A¥Í§ÞÃþªÑªí²{´¶¹M¨ü¨ì§ë¸ê±¡ºü°·Å¤§¼vÅT¡C¥»¤½¥q±N«ùÄòP¤O¬°ªÑªF³Ð³yªø´Á »ùȨúɤO»P§ë¸êªÌ«O«ù¨}¦n¤§·¾³qºÞ¹D¡C ¨È·à±d¥Ñ°J·PÁ¦U¦ìªÑªF¹ï©ó¥»¤½¥qªº«H¥ô¡A¥H¤Î¦U¦ìªÑªF¹L¥h¤@¦~¨Ó¹ï¥»¤½¥qªº¹©¤O¤ä«ù¡C
¤@¡B 2017 ¦~Àç¹B¦¨ªG ²£«~¬ã¨sµo®i·§ªp
Varlitinib ¨È·à±d¤µ¦~ºn¤§°È¬°±À°Ê varlitinib Áx¹DÀù»PGÀù¶i¤J¼Ï¯Ã¸ÕÅ綥¬q¡CÁx¹DÀù²Ä¤G½u¤T ´Á¥þ²y©Ê¼Ï¯Ã¸ÕÅç TreeTopp ¤w©ó 6 ¤ë¶}©l©Û¦¬¯f±w¡A¥»¸ÕÅç¦@±N©Û¦¬ 120 ¦ì¯f±w¡A¦p¼Æ ¾Ú¥¿±¡A¥»¤½¥q±N¥H¦¹¸ÕÅçµ²ªG§@¬°¬ü°ê¤Î¥þ²y¨ä¥L¦a°Ï¥Ó½ÐÃÄÃÒ¤§¨Ì¾Ú¡C¤µ¦~ 8 ¤ë¡A ¥»¤½¥q¤½¥¬GÀù²Ä¤@½u¤G/¤T´Á¥þ²y©ÊÁ{§É¸ÕÅç¶}©l©Û¦¬¯f±w¡A²Ä¤G´Á±N©Û¦¬ 40 ¦ì¯f±w¡A ©ó 2018 ¦~¶i¦æ¸ÕÅç¸ê®Æ¤ÀªR¡C¥»¤½¥q¥ç©ó 2 ¤ë«Å¥¬¤é¥»Áx¹DÀù¤@´ÁÁ{§É¸ÕÅ秹¦¨º¦ì¨ü ¸ÕªÌ¦¬®×¡A¦¹Á{§É¸ÕÅç¥i¯Ç¤J«ez 2018 ¦~¥þ²y©Ê¼Ï¯Ã¸ÕÅç TreeTopp ªº¤@Àô¡C¥t¥»¤½¥q©ó 9 ¤ë»P·s¥[©Y°ê¥ß¤j¾ÇÀù¯g¤¤¤ß¦X§@±Ò°Ê varlitinib º¶µ°w¹ï¨x²ÓMÀù (HCC¡A¨xÀù) ¤§Á{ §É¸ÕÅç¡C 2017 ¦~¡A¥»¤½¥q¤½¥¬ varlitinib °w¹ï²Ä¤G½uÂಾ©Ê¨ÅÀù¤§¤G´ÁÁ{§É¸ÕÅç·s¼Æ¾ÚÅã¥Ü¡AÃĪ« ¹ï¯f±w©Ò®i²{ªº¸~½FÁY¤p¦¨®Ä¸û¼Ð·ÇÀøªk¬°¨Î¡C¥»¤½¥q¥ç¤½¥¬²Ä 1b ´ÁÁ{§É¸ÕÅç¼Æ¾Ú¡A·í ¤¤½T¥ß¤F varlitinib ¦X¨ÖÂù¤ÆÀøÃĪ«¨Ï¥Î®É¤§³Ì¤j@¨ü¾¯¶q¡A¨Ï¨È·à±d±o¥H¦b«áÄòªºGÀù ¥þ²y©Ê¼Ï¯Ã¸ÕÅ礤¨Ï¥Î¦¹¤@ªvÀø¤è®×¡C
¨È·à±d©ó¤µ¦~«×¦h¶µ«n¸~½FÂå¾Ç·|ij¤¤¶i¦æ²³ø¡A¥]¬A¬ü°êÁ{§É¸~½FÂå¾Ç·| (ASCO) ¤Î ¼Ú¬wÁ{§É¸~½F¾Ç·|¤§¨È¬w¤j·| (ESMO)¡A¥»¤½¥q¤§²Ä¤G´Á¨ÅÀù¬ÛÃöºKn®ü³ø¥çºaÀò ESMO ²¾ÂàÃþ¨ÅÀù¤§³Ì¨Î®ü³ø¼ú¡C
ASLAN003 ASLAN003 ¤§ªvÀø»â°ì³vº¥¦¨¬°¸~½FÂå¾Ç¤¤ªº¼öªù»â°ì¡A¼Æ®a¥Í§Þ¤½¥qµÛ¤â¶}µo DHODH §í¨î¾¯¡A¦ý¶i«×¸¨«á ASLAN003¡C¤µ¦~¥»¤½¥q«Å¥¬Á{§É«e¸ÕÅç¼Æ¾ÚÅã¥Ü ASLAN003 ¥i¾A¥Î ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f¡A¶i¦Ó»P·s¥[©YÀù¯g¬ì¾Ç¬ã¨s©Ò (CSI)¡B·s¥[©Y°ê¥ß¤j¾Ç Àù¯g¤¤¤ß (NCIS) ¦X§@¡A±N²`¤J±´°Q ASLAN003 ©ó¦å²GÀù¯gªºªvÀø¼ç¤O¡A¨Ã©ó 11 ¤ëÀò±o±Ò°Ê«æ©Ê°© Åè©Ê¥Õ¦å¯f¤G´ÁÁ{§É¸ÕÅ礧®Öã¡A¹wp±N©ó 2018 ¦~µy±ß±o¨ì´Á¤¤¼Æ¾Ú¡C
ASLAN004 ¥»¤½¥q¤w©ó¤µ¦~±Ò°Ê¥Ó½ÐÁ{§É¸ÕÅç¼f¬d (IND) ©Ò»Ý¤§ GLP ¬r²z¸ÕÅç¡A¥Ø«e¥¿¬°¹wp¦b 2018 ¦~µy±ß®i¶}ªº²Ä¤@´Á¸ÕÅç·Ç³Æ¬ÛÃö¸ê®Æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/23 ¤W¤È 11:12:33
²Ä 161 ½g¦^À³
|
ÁÂÁÂ¥x¿}¤jªº¸Ô²Ó¤ÀªR~~
§Úªº²L¨£¬OAS0001+Paclitaxel+Carboplatin-2´Á¼Æ¾ÚY¬O¹F¼Ð,´N¾Ö¦³±j¦Ó¦³§QªºÄw½X»P¤j¼t¸û¶q©Î¦X§@(²¦³ºHer+MBC¨ÅÀù¥ÎÃĬO¤jÃÄ),¦]¬°:
TrastuzumabyªýÂ_Her2-ù¤óÃļt Pertuzumab ªýÂ_HER2/HER3-ù¤óÃļt AS0001 ªýÂ_©Ò¦³ªxHER®a±Ú-¦Ñ·à
¦Ñ·à¥i¸òù¤óÃļt¦X§@,¤]¥i¸ò¨ä¥L¤j¼t¦X§@·mù¤óªº¦a½L~~«ç»òª±³£¤£·|¿é
¥H¤W¨Ñ°Ñ¦Ò~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gª£¦Ì¯»10146792 |
µoªí®É¶¡:2018/5/22 ¤U¤È 04:16:17
²Ä 160 ½g¦^À³
|
ADRªº¼W¸ê³¡¤À¥H©ó¤W¶g¦X¨Ö¤J¥xªÑ¡A¬G¥~¸ê¤ñ¨Ò¼W¥[¡A¥Ø«e·à·à¯uªº¤£¤Ó§®¡AADR¤@ª½³QÀ£¨î6.2¬ü¤¸¥H¤U¡A¤ÏÆ[arql¤@ª½¨gº¦¡A6¤ëªìªº¥Í§Þµoªí§¹¥þ¨S¤ÏÀ³¦ÜªÑ»ù¡A¥i¯àn¥ð®§«D±`¤[ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/22 ¤U¤È 03:08:54
²Ä 159 ½g¦^À³
|
§Ú¤U³æªº¨é°ÓAPP¤W±ªº¸ê®Æ ·à¤lªº¥~¸ê«ùªÑ ¦Û16¤é¦Ü¤µ ´N¤@ª½Åã¥Ü¦Ê¤À¦Ê«ùªÑ 15¤é¤§«e³£¬O¦Ê¤À¤§82 ¤£ª¾¹Dµo¥Í¤°»ò¨Æ¤F
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/21 ¤U¤È 11:49:49
²Ä 158 ½g¦^À³
|
©t¨àÃĤj
A 2018 ASCO : Dose finding study of varlitinib ¡Ó trastuzumab with carboplatin/paclitaxel in advanced solid tumors.
This is a phase 1b dose confirmation study to determine safety and early efficacy signals of V ¡Ó T combined with weekly P 80mg/m2 and C AUC = 2
2018 06 04 ASCO ¬ã¨sµoªí µ²½×¬Ý¥X weekly V ¡Ó T combined with P 80mg/m2 and C AUC = 2
µo²{¥[¶PÀù¥¬O¦w¥þªº , Aslan 001 ¦b±ÀÂ˾¯¶q¤U»P¤Ó¥¬vµµ§ü¾J¹ï HER2 ¶§©Ê¨ÅÀù¬O¦³®Äªº , ·Ç³Æµû¦ô¤T¦X¤@§@¬°·s»²§UÀøªk
Conclusions: The RD of V combined with P is 300mg BD int, and is active in HER2+ MBC; T can be added safely. The triple combination will be evaluated as neoadjuvant therapy in HER2+ breast cancer
B 1/2 ´ÁÁ{§É¸ÕÅç :
Official Title: Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer
Study Start Date : March 2015 Estimated Primary Completion Date : March 2018 Estimated Study Completion Date : March 2019
1½T©w³Ì¨Î¾¯¶q 2 ¥i¥H¦w¥þ»P¶PÀù¥Áp¦X¥ÎÃÄ 3 ¬°¥¼¨Ó¤T¦X¤@ÁpÃÄ·s»²§UÀøªk«ü¥X¤è¦V (¬O§_¦³¨ú¥N¶PÀù¥ªº¼ç¤O»Ý¶i¦æÁ{§É¸ÕÅç ¤@¨B¤@¨B¦V«e¨«)
4¬O¤£¬O´Á¤¤¤ÀªR§Ú¤£½T©w , ¤Ï¥¿ 2019 3 ¤ë ´N·|§¹¦¨HER2 ¶§©Ê¨ÅÀù¤G´ÁÁ{§É ( ©Û¦¬stage 1 - stage3 )
Drug: Paclitaxel + Carboplatin + ASLAN001
Phase I
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle PO ASLAN001 daily continuously (starting dose 500mg BID)
Phase II
•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks
Followed by:
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/21 ¤U¤È 01:31:16
²Ä 157 ½g¦^À³
|
¥xÁÞ¤j,½Ð°Ý³o¦¸¤½§Gªº¼Æ¾Ú¨ä¤¤300mgªº³¡¥÷¯àµø¬°2´Áªº´Á¤¤¼Æ¾Ú¶Ü?§Ú¬Ý³o¹êÅç¬O1,2´Á¦X¨Ö°õ¦æªº ?
Ápµ²¦p¤U :
clinicaltrials.gov/ct2/show/NCT02396108 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/21 ¤U¤È 12:10:54
²Ä 156 ½g¦^À³
|
ASLAN001¬O°w¹ï«üHER2¶§©ÊÂಾ©Ê¨ÅÀù«á½uªvÀø¬°¥D¡A²Ä¤G½uªvÀøªºÀø®Ä¥i°Ñ¦Ò¥h¦~©³ªk»¡Â²³ø¡A¨È·à±d¨ÅÀù¬ãµo¥Ø«e»P¯E¹©¤£¤¬¬ÛÄvª§¡A¨È·à±dn®i²{Áx¹DÀù¡AGÀù¡A¨ÅÀùªº¼Æ¾Ú¥H´£°ª±ÂÅvª÷»ù½Xªº¥ø¹Ï¤ß¥O¤H¨ØªA¡C ¥H¤W¨â«h¤À¨É¡A¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/21 ¤W¤È 11:55:41
²Ä 155 ½g¦^À³
|
¤»¤ë¥|¤énµoªíªº Her2¶§©ÊÂಾ©Ê¨ÅÀù«á½uªvÀøªº¼Æ¾Ú·¥¦³¼ç¤O¡]¯f±w¥ý«e¤¤¦ì¼Æ¥Î¤F4½u¡APRÁÙ¦³¦Ê¤À¤§35¡^ºKn¦bµ²½×ªí¹F¤F·|µû¦ôV+P+T ¤TÃÄÁp¦X§@¬°Âಾ©Ê¨ÅÀù·sªº»²§UÀøªk¡C
abstracts.asco.org/214/AbstView_214_220585.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2018/5/21 ¤W¤È 10:47:39
²Ä 154 ½g¦^À³
|
¦U¦ì·à¤Í¤È¦w ³o°}¤l¤u§@¦£¡A¨SªÅºÞ¤â¤¤«ùªÑ ·à¤l¤]¤W¤W¤U¤U¤S¶^¨ì37¥ª¥k (¤§«eªº·¸»ù¤w¸g¦¬ÀĸòADR¤w¸g´X¥G¦P»ù) ¤£ª¾¹D²³·à¤Í¤â¤¤·à¤lªº¦¨¥»§¡»ù¤j·§¦bþ¸Ì?
¤p§ÌÆZ·Q¦b³oÃä°µ¥[½X¡A¤Sı±o§Þ³N±«ÜÁV ¬O»¡§ë¸ê·sÃĤ]¤£¥ÎºÞ¤°»ò§Þ³N±´N¬O |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/18 ¤W¤È 10:59:49
²Ä 153 ½g¦^À³
|
ªüÁø©j¹ï·à¤lªº¬Ýªk³o¦¸À³¸Ó¬O¹ïªº³á~~³o¦¸ªº2´Á´Á¤¤¼Æ¾Ú³þ©wªvÀøHER+ªº©ú½T¤è¦V,¥[ªo~~·à¤l
MBC¼Æ¾Ú:20/37 had HER2+ metastatic breast cancer (MBC) with median 4 (0-14) prior treatment lines. 7 achieved partial response (PR) and 3 stable disease (SD); 6 had disease control with single agent V for a median 7.0 more months (4.3 ¡V 13.3) after chemotherapy ceased. 2/17 with other tumor types achieved PR (HER2- MBC = 1, NSCLC = 1). 3/10 patients (HER2+ MBC = 2) in the V 300mg BD int cohorts achieved PR. No correlation was seen between V and P mean AUC (ng.h/mL) in those with and without DLTs (V 10336.5 vs 20758.8, p = 0.21; P 4882.1 vs 5197.6, p = 0.77). No interaction was seen between V dose/schedule with P PK. Conclusions: The RD of V combined with P is 300mg BD int, and is active in HER2+ MBC; T can be added safely. The triple combination will be evaluated as neoadjuvant therapy in HER2+ breast cancer.
¥H¤W¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~¥t¥~ÁÂÁÂ¥xÁÞ¤jªº°T®§¤è¦V |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GRock10135634 |
µoªí®É¶¡:2018/5/18 ¤W¤È 10:18:52
²Ä 152 ½g¦^À³
|
«HªüÁø±o®M©Ð ¨C¦¸³£»¡¦³§K¶O¬¡°Ê¯d¨¥´N±a§A¶R¶i·s¼Ðªº µ²ªG²z±M¥´¨Ó´N¬On§A¤J·|û¡A§Ú»¡ªü¤£¬O§K¶O±a¾Þ§@¤@¦¸ µM«á²z¥Ñ¤@°ï§Ú´N±¾¹q¸Ü ¨ä¹ê¤£¬O¯uªºn¸òµÛ¶R¡A¥u·Qťť¥¦Ì¦b·d¬Æ»ò©Û¦Ó¤w |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸²µåô10146373 |
µoªí®É¶¡:2018/5/18 ¤W¤È 08:30:29
²Ä 151 ½g¦^À³
|
ªüÁø¬Q¤Ñ»¡¤â¤W¦³¯E¹©¡BÃĵØÃÄ©M¨È·à±dªº »°§Ö¥h§ä¦o ¦o·|À°§A¥þ³¡Ä¹¦^¨Ó Ŧ^§Aªº±m¦â¤H¥Í |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/18 ¤W¤È 06:09:26
²Ä 150 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.24 USD +0.040 (0.65%) 5¤ë17¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/17 ¤U¤È 11:24:23
²Ä 149 ½g¦^À³
|
§ó¥¿ Ó¤H±À¦ô¤µ¦~6¤ë¨ì©ú¦~3¤ë¬O·à¤lÁ{§É¼Æ¾Úµoªíªº°ª®p´Á ¤j®aÀ³±K¤ÁÃöª`
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/17 ¤U¤È 11:11:30
²Ä 148 ½g¦^À³
|
©t¨àÃĤj ¨È·à±d¬O·s¥[©Y¨Ó¥x¤W¥«ªº¥Í§Þ¤½¥q¡A°ê»Ú¤Æµ{«×¬Û·í¦n¡A¥[¤W³o¦¸¥H¨C³æ¦ì7.03¬ü¤¸§¹¦¨¶Ò¸ê¡A²ü¥]º¡º¡¡A ¤µ¦~ªºAACR. ASCO³£·|µoªí¼Æ¾Ú¡A¥¼¨Ó6-9Ó¤ë¬O¼Æ¾Úµoªí°ª®p´Á¡A¤½¥q¤½§iªº¼Æ¾Ú¡A°ê¤º¥~´CÅé³£·|³ø¾É¡A¦]¬°·à¤l°ê»Ú¤Æµ{«×°÷¡C ¥H¤W¸ê°T ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/17 ¤U¤È 02:39:57
²Ä 147 ½g¦^À³
|
·s¶i«×¥X²{: 1. »¡©úÁxºÞÀù¿é¯Ã¸ÕÅ礴¦b¶i¦æ 2.µ²¦Xµµ§ü¾J¦X¨ÖªvÀø¦b¨ÅÀùªº¦³®Ä©Ê
ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO
globenewswire.com/news-release/2018/05/17/1507867/0/en/ASLAN-Pharmaceuticals-to-Present-Two-Posters-on-Varlitinib-at-ASCO.html |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/17 ¤W¤È 09:20:23
²Ä 146 ½g¦^À³
|
²×©ó¦³¤H¨ü¤£¤F¥hµo¨¥¤F,¥H¤U~~~Æg
stocktwits.com/symbol/ASLN
¯u·Q§â¥xÁÞ¤j³o½g½Ķ¦¨^¤å¶K¹L¥h~~¤£¦n·N«ä¥xÁÞ¤j,ɥΤ@¤U~~
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2018/5/10 ¤U¤È 11:44:12²Ä 136 ½g¦^À³ ±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O
1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª 3 ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ70% 4 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³§¹¦¨Á{§É¸ÕÅç
5 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O 6 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,±ÂÅv¥X¥h½æÓ¦n»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g¶O¤£¯Ê¤~¬O¥»½è 7 ¨È ·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q, ¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q
seekingalpha.com/news/3346036-arqule-licenses-derazantinib-basilea-pharma-327m-shares-9-percent-premarket
files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf
¥H¤W¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/17 ¤W¤È 07:44:35
²Ä 145 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.21 USD −0.040 (0.64%) 5¤ë16¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/16 ¤U¤È 11:56:53
²Ä 144 ½g¦^À³
|
¤»¤ë¥H«á·|¦³¨xÀù AML GÀù ¤@½uÁx¹DÀù ¤¤°ê¤G½uÁx¹DÀù ¬ÛÃöÁ{§É¼Æ¾Ú¤½§i
¥Ø«e°ê¤º¥Í¥~§Þ¤½¥q¶Ò¸ê¤£©ö,Leo ¶Ò¸ê§¹¦¨²ü¥]º¡º¡, ½Í§P¹ê¤O¤j¼W
°ê¥~ADR¹ï¬ÛÃöÁ{§É¼Æ¾Ú©Î ±ÂÅv, ¨ÖÁʵ¥¤½§i·|µ¹¤©À³¦³ªº¤ÏÀ³, ±`±`¬Ý¨ì°ê¥~¥Í§Þ¤½¥q¤½§iÁ{§É¼Æ¾Ú©Î±ÂÅv ©Î ¨ÖÁʪѻùº¦´TµL¤W
¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GRock10135634 |
µoªí®É¶¡:2018/5/16 ¤W¤È 11:29:14
²Ä 143 ½g¦^À³
|
¦ý§Úı±o¬ü°ê¤H¬Ý¥Í§Þ¤ñ¸û«ÈÆ[ ¬Û¹ï¥xÆW´²¤á¬Ý¥Íp¥uÃö¤ß¦³¨S¦³ÁÈ¿ú¤£¬Ý»·´º ¥xÆW¥Í§ÞªÑ¯uªºº¡¥i¼¦ªº |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/16 ¤W¤È 11:14:43
²Ä 142 ½g¦^À³
|
Rock¤j, ¤£¯àµo^¤å«°T¡]³o¬O²Î¤@ÃҨ骺»¡ªk°Ú¡^,¥i¥Hµo¤¤¤å°T®§°Ú¡]°£«D¬OµL°T®§¥iµo¡ã¡^¡ã¿U¥xÆW¤~¬O¥DÅéù,ADR¥u¬OªþÄÝ...«¢«¢..¥i¯à¬O§Ú¤@´[±¡Ä@°Ú~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GRock10135634 |
µoªí®É¶¡:2018/5/16 ¤W¤È 11:03:49
²Ä 141 ½g¦^À³
|
¨S¿ìªk¡A¨È·à±dADR¤W¬O¦³25Ó¥æ©ö¤éªº½pÀqÅv ©Ò¥H³o¬q´Á¶¡µLªkµo¥¬¥ô¦ó«¤j°T®§¡A¥u¯àµ¥«Ý6¤ë¤W¦¯«á¬Ý¬Ý¤½¥q¦³µL®ø®§µo¥¬
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/16 ¤W¤È 09:42:14
²Ä 140 ½g¦^À³
|
To : ¥xÁÞ¤j©Î¦U¦ì¦³¤ßªº¤j¤jÌ~~~
¥i¥H¨ì¬ü°êªº°Q½×°Ï¸ò¥L̲á²áASLNªº»ùȦó¦b¡H§Úµo²{¬ü°êªº¥L̦n¹³«Ü¦h³£¤£À´©Î¬O¤£ª¾±qþÀò±o¸ê°T¡ã¡ã¥»¨Ó¬O·Q¥Ñ¬ü°ê¢Ï¢Ò¢à±a°Ê¥xÆW»ùÈ,¬Ý¨Ón¥Ñ¥xÆW±a°Ê¬ü°ê¤F....
stocktwits.com/symbol/ASLN
¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~¥D¤O¤]½Ð§A¦hÀ°¦£¤@¤U³á¡I¡I¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/16 ¤W¤È 08:12:41
²Ä 139 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.25 USD −0.14 (2.19%) 5¤ë15¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥²³Ó«È10144050 |
µoªí®É¶¡:2018/5/15 ¤W¤È 05:37:46
²Ä 138 ½g¦^À³
|
ASLAN PHARMACEUTICALS ADR REP 5 ORD NASDAQ: ASLN 6.39 USD −0.11 (1.69%) 5¤ë14¤é ¤U¤È4:00 [EDT] ¡P §K³dÁn©ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/12 ¤W¤È 10:26:30
²Ä 137 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤jºëÅPªº¤ÀªR~~»ùÈÁ`·|¦b²ö¦Wªº§QªÅ¤¤²f·Ò¥X¨Ó....¥t¥~5/11¤t´¶ªº¥´À£ÃÄ»ù¬Fµ¦,À³¬O°w¹ï¤¤¶¡°Óªºé«d¤U¤â,À³¹ï©t¨àÃÄ·sÃļvÅT¤£¤j,¦A¥[¤WFDA·sÃļf®Ö¬Ò¦³¥[³tªº¸ñ¶H,°Ñ¦Òºô§}¦p¤U :
www.epochtimes.com/b5/18/5/11/n10385655.htm
¨Ñ°Ñ¦Ò,¤Å¥H¦¹¬°ªÑ²¼¶i¥X¨Ì¾Ú~~~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/10 ¤U¤È 11:44:12
²Ä 136 ½g¦^À³
|
±q Arqule ¤G½uÁx¹DÀù±ÂÅv¨óij§Ú¬Ý¨ì¨È·à±d ASLAN 001 ªº»ùÈ»P¼ç¤O
1 ³oÁûÃľA¥Î¨x¤ºÁxºÞÀù FGFR ¬ðÅÜ ( 40% -50% X 10% -20% = 4% -10% ) ¦û Áx¹DÀù10% ¥H¤U 2 «eª÷1000¸U¬ü¤¸ ¨½µ{ª÷ 3.26»õ¬ü¤¸ «eª÷/ ¨½µ{ª÷ 1/32.6 ¦³ÂI°¾§C ªí¥Ü ±ÂÅv¶i¨Óªº¤½¥q±Ä¨ú¤ñ¸û«O¦u ºA«× , «eª÷/ ¨½µ{ª÷ ¤ñ²v¶V°ªªí¥Ü±ÂÅv¶i¨Óªº¤½¥q¹ï³oÁûÃÄ¥¼¨Óµo®i«H¤ß«×¶V°ª 3 ¨È·à±d ASLAN 001 ¾A¥ÎÁx¹DÀù¤H¤f¦û¤ñ70% 4 derazantinib 2021 ¦~¤~·|§¹¦¨Á{§É¸ÕÅç ASLAN 001 2018 ¦~©³§¹¦¨Á{§É¸ÕÅç
5 §Ú¬Ý¨ì¨È·à±dªº»ùÈ»P¼ç¤O 6 ADR»ù®æ¤W¤W¤U¤U¬O·n®Ìªº¼v¤l,±ÂÅv¥X¥h½æÓ¦n»ù¿ú,¯à©µÄò¥¼¨Ó¤Q¦~¬ãµo¸g¶O¤£¯Ê¤~¬O¥»½è 7 ¨È ·à±d¤£¦ý¬O²Ä¤@®a¦b¬ü°ê±¾µPªº¥xÆW¥Í§Þ¤½¥q, ¤]¦³«Ü¤j¼ç¤O¦A³Ð°ê¤º±ÂÅvª÷·s°ªªº¥xÆW¥Í§Þ¤½¥q
seekingalpha.com/news/3346036-arqule-licenses-derazantinib-basilea-pharma-327m-shares-9-percent-premarket
files.shareholder.com/downloads/ARQL/0x0x952609/7FD86678-3664-476F-A556-8B92F36E9C80/Derazantinib_ARQ_087_FGFR_Inhibitor_-_August_2017.pdf
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ½Ð¤Å·í¬°§ë¸ê¨Ì¾Ú
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GMBE10145047 |
µoªí®É¶¡:2018/5/9 ¤W¤È 02:25:05
²Ä 135 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:107/05/08 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¨Ì³W©óµo¦æ¤é´Á¤½§i¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ ¤§¬ÛÃö¸ê°T¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§µo¦æ±ø¥ó¦p¤U¡G (1) µo¦æ¤½¥q¡G¨È·à±dªÑ¥÷¦³¤½¥q (2) µo¦æºØÃþ¡G²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ (3) µo¦æÁ`ª÷ÃB¡G¬üª÷42,180,000¤¸ (4) µo¦æÁ`¼Æ¡G¹ê»Úµo¦æ³æ¦ì¼Æ¬°6,000,000³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q´¶ ³qªÑ5ªÑ¡AÁ`¹ê»Úµo¦æ´¶³qªÑªÑ¼Æ¬°30,000,000ªÑ¡C (5) ¨C³æ¦ìµo¦æ»ù®æ¡G¬üª÷7.03¤¸ (6) ¨CªÑ»ù®æ¡G§é¦X¬°·s»O¹ô¬ù41.72¤¸(«ö¬üª÷§I·s»O¹ô¶×²v=0.03369)¡C (7) µo¦æ¤é´Á¡G107/05/08 (8) ¥æ©ö¦aÂI¡G¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò (9) µo¦æ¦aÂI¡G¬ü°ê (10)¦s°U»È¦æ¡G¼¯®Ú¤j³q»È¦æ (11)q»ù¤é¡G107/05/04 (12)¥»¦¸²{ª÷¼W¸ê°ò·Ç¤é¡G¥»¦¸²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ©ó107¦~05¤ë 08¤é¦¬¨¬ªÑ´Ú¡A¨Ãq107¦~05¤ë08¤é¬°²{ª÷¼W¸ê°ò·Ç¤é¡C (13)¸êª÷¹B¥Îpµe¤Î¹wp¥i¯à²£¥Í®Ä¯q¡G¤@¯ë¥ø·~¥Î³~-«·sñq±ÂÅv¦X¬ù¡BÃĪ«¬ãµo ¤Î°Ó«~¤Æ¤Î·sÃĬdÅçµn°O¥Ó½Ð¡A«ez¤T¶µpµe¹wp½Õ¾ã±ÂÅv¥æ©ö¬[ºc¡B¶i¦æ¬ãµo »s³y¬¡°Ê¡BÁʶR±M§Q¡B«Ø¥ß°Ó·~¼Ò¦¡¥H´£¤ÉªÑªF§Q¯q¡C (14)¹ïªÑªFÅv¯q¤§¼vÅT¡G¹wp±N´£¤ÉªÑªF§Q¯q¡Aµo¦æ·sªÑ30,000,000ªÑ¡A¥[p¥Ø«e ¹ê¦¬ªÑ¥»130,128,940ªÑ¡A¨ä¨CªÑµ|«e¬Õ¾lµ}ÄÀµ{«×18.73%¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/8 ¤U¤È 11:46:16
²Ä 134 ½g¦^À³
|
¤µ±ßÆZ±jªº¡AADRº¦´T§Ö¹Gªñ¦Ê¤À¤§12 www.marketwatch.com/m/quote/asln
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/8 ¤W¤È 10:09:55
²Ä 133 ½g¦^À³
|
«¥Ì³o¨Ç°Q½×ª©,«Ü¦h¥D¤O³£·|¨Ó³oÃäÆ[¹î°Ê¦V,Äw½X¥L¤ñ§Ú̦æ,¦ý°ò¥»±ªº¤ÀªR©Î³\¬O§ÚÌ¥i¥H¬ð¯}ÂI~~¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2018/5/8 ¤W¤È 08:58:00
²Ä 132 ½g¦^À³
|
¤µ¤Ñ¨S·N¥~À³¸Ó¤S¬O¤@®Ú¶^°±¡AADR²Ä¤G¤ÑÁÙ¬O¨«¶^¡AÁöµM¶^¶ÕÁͽw¤F¡A¥u¦³¶^2%¦h¡A¦ý¬O«e¤Ñ¶^ªº20%¥[¤W§é»ù10%¡A§Ú¬Ý¥i¯à¯uªºn¦^´ú«e¤@ªi§CÂI30.8¤F¡A°£«D³Ìªñ¦³Ô£¦n®ø®§¤½¥¬¡A§_«hn¤îÃÁÙnµ¥µ¥! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJames146310146097 |
µoªí®É¶¡:2018/5/7 ¤W¤È 11:21:49
²Ä 131 ½g¦^À³
|
½Ð°Ý¤p³Á¥S¡A±z©Ò¬Ý¨ìªº¦n®ø®§¬O«üþ¤@¤è±?
³oªi¨È·à±d±q§CÂI¤Ï¼u´N¬OÂǵۦb¬ü°êµo¦æ ADR¡A§Æ±æÂÇ¥ÑADR·¸»ùµo¦æ¥B¤Wº¦¨ì¦X²zªº¤ô·Ç±a°Ê¥xÆWªÑ»ù(·í®É¥«³õ´N¬OÄjº©³o¼Ëªº®ðª^¤~§âªÑ»ù±À¤É¨ì60¥H¤W)¡A²{¦b³o¼Ëªºµo®i¡A¥D¤OÅK©w¤w¸g¨«¤H¡A¦Ó¬Û«H³o¼Ë½×½Õªº´²¤á¡A¥u¯à¤SnW¦u´H½`¡A°£«D¤½¥q·sÃĦ³¬ð¯}©Êªºµo®i¡A§_«h¤j·§¤Sn´ú¸Õ«eªi§CÂI¤F¡C
§Æ±æ¤½¥qªñ´Á¯àµoªí¥¿±¬ã¨s¼Æ¾Ú¡AÅýªÑ»ù¤Ï¬M¤½¥q¦bªk»¡·|©Ò´£¨ìªº»ùÈ¡A¤]¥i¬@±Ï¦V¤U¨I²_ªºªÑ»ù©M¦]¬Û«H¤½¥q¤ä«ù¤½¥q«oºG¾D®M¨cªºªÑªFÌ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p³Á10146801 |
µoªí®É¶¡:2018/5/7 ¤W¤È 10:40:39
²Ä 130 ½g¦^À³
|
©ú©ú¬O¦n®ø®§¡A´CÅé«o¼g±o¦n¹³¦³¦hÁV¿|¨Ì¼Ë |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJames146310146097 |
µoªí®É¶¡:2018/5/7 ¤W¤È 10:14:46
²Ä 129 ½g¦^À³
|
ì©lªÑªF¦b¥xÆWIPO²Ä¤@¤Ñ¥i¯à´N¤w©ß¥X«ùªÑ¡A¤£µM«ç»ò¥i¯à²Ä¤@¤Ñ´N¶^¯}©Ó¾P»ù¡A¨È·à±dÀ³¸Ó¤½¶}¼á²M¦Û¤v¬O§_¦³ÄY®æ±±ºÞì©lªÑªFªº«ùªÑ¡A¦pªG§Q¥Î¤½¶}¥«³õÄw¸ê(¥xÆW+NASDAQ)¡A«o¤£¬ù§ôì©lªÑªF®M§Q¦æ¬°(¥ý½æ«á¶R)¡A±NÄY«¶Ë®`¨ì·sªÑªFªºÅv¯q¡A¤]§Æ±æ¥DºÞ¾÷Ãö¯à°÷Ãöª`¨ÃªÈ¥¿. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GJames146310146097 |
µoªí®É¶¡:2018/5/7 ¤W¤È 10:05:05
²Ä 128 ½g¦^À³
|
·Pı³o®a¤½¥q¦b´CÅé³y¶Õªº¤è¦¡¦³°ÝÃD¡A¹L¥h¤@ª½¦Û§Ú·Pı¤Ó¨}¦n¡A³o¦¸¤j®a´Á«Ý¥h¬ü°ê¤ñ»ù¨ú±o¦X²zªºBenchmark¡A µ²ªG·m¥ýµo¦æ ADR «o¸¨±oº¤é¤j¶^ªºµ²ªG¡A¬O§_¾Þ§@ªº¹L©ó«æļ¡A¥t¥~¥~¬É¹ï¨È·à±dªººÃ¼{¡A¬O§_¦³¥R¤À·¾³q¸ÑÄÀ? §Æ±æ¤½¥qµu´Á¶¡¯àÄÀ¥X¸û¥¿±ªº¼Æ¾Ú¡A¥H¤ä¼µ¶^¶^¤£¥ðªºªÑ»ù¡A¦Ü¤Ön¥ýÃ¦í¥«³õ»ù®æ§a¡A§_«h¹ï¤½¥q¥¼¨ÓÄw¸ê±N·|¬OÃø¤W¥[Ãø. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2018/5/7 ¤W¤È 10:04:15
²Ä 127 ½g¦^À³
|
Ó¤H·PıADR¦b¬ü°ê²Ä¤@¤Ñ¶^20%ÁÙ¬O¦³ÂI¤£¸Ñ¡A°²³]ì©lªÑªFn½æªÑÀ³¸Ó¨S¥²n¦b¬ü°ê½æ§a¡A¦]¬°n§é»ù10$¡A¦ý¬O¥i¥H¦b²Ä¤@¤Ñ´N¯à©ß¥X¨º»ò¦h³f¤£¬O¤]¥u¦³ì©lªÑªF¦³¶Ü? ¬°¦ó¥¦n¦b¬ü°ê½æ©O? Ãø¹D¬O¦]¬°¬ü°ê¨S¦³º¦¶^´T¨î¡A·Qn¤@¤f®ð¥X²M¡A¦]¬°¨S¦³Äw½X¥i¥H¬Ý¡A¤£ª¾¹DADR²Ä¤@¤Ñ¬O½Ö½æªº¡A¥u¬O¦³ÂI·Q¤£³q¦Ó¤w! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/7 ¤W¤È 09:48:48
²Ä 126 ½g¦^À³
|
¥¢±æªº¤j½æÀ£¬OÃø§K,«áÄò§Æ±æ¦³§ó¦³¤O¼Æ¾Ú¤Î±¹¬I(¦p±ÂÅv©ÎÀu¶VªºÁ{§É¼Æ¾Ú),¤£µM¥Ã»·«ÁÐ¥h¦~¤W¥«ªºª¬ªp~~²Ö |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/7 ¤W¤È 08:47:29
²Ä 125 ½g¦^À³
|
·à¤l¦b¬ü±¾µPªÑ»ùªí²{¤£¦p¹w´Á¬O¤@®Éªº¡A½Öª¾¹D¤µ¤Ñ±ß¤Wªºªí²{¤S·|¦p¦ó?Ó¤H»{¬°³Ì«nªº¬O¨È·à±d²{¦³ªº¸êª÷¥[¤W³o¦¸¦b¬ü°êµo¦æªº¦s°U¾ÌÃҩҶҨ쪺¸êª÷¡AÅý¤½¥q¥i¥H¤@®iªø¤~¡AÅý¥¼¨Ó¦U¶µ¬ãµo¶¶§Q¶i¦æ¡A¦³¨¬°÷ªº²{ª÷¦b±ÂÅv½Í§P©ó¨ÖÁʤW¤]¬O¤@ºØ±j¦Ó¦³¤OªºÄw½X¡C¤£¬O¶Ü? ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gª£¦Ì¯»10146792 |
µoªí®É¶¡:2018/5/5 ¤W¤È 12:45:55
²Ä 124 ½g¦^À³
|
ÁöµM©w»ùÅý§ÚÃø¹L¡Aµu´Á·|¦³½æÀ£¯B²{¡A¦ý¬JµM¯à¤ñ¥x·LÅé§ó¦¤W¥«¡A¬Û«H¦¹ªÑ¤ñ¹w¦ô7.46¤¸ªº¥x·LÅé§ó¦³Ãzµo¼ç¤O¡A¥«³õ¼ç¤O¤Î¶i«×¤ñ¬Û¦P²£«~ªºarqule§ó¦n¤]§ó»â¥ý¡A´Á«Ý³æªÑ»ùÈ¥ý¶W¶VArQule,¦A¤ÏÀ³¥XÃÄ«~§ó¤jªº¥«³õ»ùÈ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gª£¦Ì¯»10146792 |
µoªí®É¶¡:2018/5/5 ¤W¤È 12:11:47
²Ä 123 ½g¦^À³
|
¨È·à±d«Å¥¬§¹¦¨¬ü°ê¦s°U¾ÌÃÒq»ù ±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬§¹¦¨¬ü°ê¦s°U¾ÌÃÒ(ADS)q»ù¡A¨C³æ¦ì¹ê»Úµo¦æ»ù®æ¬°¬üª÷7.03¤¸¡A¹ê»Úµo¦æ³æ¦ì¼Æ¬°6,000,000³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¨È·à±d-KY´¶³qªÑ5ªÑ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/4 ¤U¤È 08:31:21
²Ä 122 ½g¦^À³
|
6497Ó¤H¬ã§P·|¬O°ê¤º²Ä¤@®a¦b¬ü°ê±¾µP¨Ã¶}©l¥æ©öªº¥Í§Þ¤½¥q¡AÅý¯u¥¿ªº»ùȦb§óÄ£²´ªº°ê»Ú¥«³õ¯u¹êªº¤ÏÀ³ ¥H¤W¤À¨É¡A¶È¨Ñ°Ñ¦Ò ¨È·à±d·sÃĬãµo¶i«×»PADR±¾µP¬ÛÃö¸ê°T½Ð¥H¤½¶}¸êÆ[´ú¯¸¤½§i¬°·Ç
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/4 ¤U¤È 08:15:56
²Ä 121 ½g¦^À³
|
¥t¥~½Ð¤j®a·Q·Q¡A¤G½uÁx¹DÀù¨Ì¾Ú¤½¥q¹w¦ô¼ç¦b¥«³õ¦³14»õ¬ü¤¸¡A¤@½uGÀù30»õ¬ü¤¸¡A¥«³õ¼ç¤O¤]¤£¿éµ¹³Ìªñ¶W¶V300ªº4147 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/5/4 ¤U¤È 07:54:41
²Ä 120 ½g¦^À³
|
6497¦b¬ü°êµo¦æADRÁÙì¤@ªÑ¬O1.61¬ü¤¸¡A»P¦P¼Ë¬ãµoÁx¹DÀùªºArqule ¤µ¦¦¬2.63¬ü¤¸¡A¦³1.02¬ü¤¸®t¶Z¡C ¤µ¤Ñ6497°ê¤º¦¬½L¤w¸g§C©ó¹w¦ô¤W¥«»ù(1.61x29.7=xx ¨Ì¾Ú¤½¥q³W¹º¤»¤ë¶}©l¨ì¦~©³¦³¨xÀù¡AAML,GÀù¡A¤¤°êÁx¹DÀù¼Æ¾Ú¤½§i¡Aȱo±K¤Áª`·NADR¶}½L¡C ¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gª£¦Ì¯»10146792 |
µoªí®É¶¡:2018/5/4 ¤U¤È 05:36:14
²Ä 119 ½g¦^À³
|
www.nasdaq.com/markets/ipos/activity.aspx?tab=upcoming 8.05¤¸¬O¥Î4¤ë¬Y¤Ñ¦¬½L»ù5¿¤Î·í¤é¶×²v¬°¥D ²{¦b¥u¯àµ¥ADR¬O§_¯à¤ÏÀ³¥X°ª©óArquleªÑ»ùªº»ùÈ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/5/4 ¤U¤È 03:46:52
²Ä 118 ½g¦^À³
|
³oADRªºµo¦æÀ³¸Ó¬OT+1¤~¹ï,¨ä8.05À³¥u¬O°e¥óªº¹w¦ô»ù....ª©¤WY¦³¤j¤j¤§¨ì§ó¶i¤@¨Bªº°T®§,½Ð¤£§[¤À¨É°Ú~~
¥H¤W¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gkenken10138351 |
µoªí®É¶¡:2018/4/30 ¤W¤È 09:28:13
²Ä 117 ½g¦^À³
|
4/30 Aslan Pharmaceuticals Ltd (ASLN) will issue 7.5 million shares at $8.05 Thursday on the Nasdaq. The Singapore-based biotech develops oncology therapeutics for prevalent diseases in Asia and orphan indications in the U.S. and Europe |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/4/19 ¤U¤È 01:46:50
²Ä 116 ½g¦^À³
|
¥i¤ñ¹ï2018.01ªk»¡·|ÀÉ®×»P¥xÁÞ¤jªº¤ÀªR~~§ó¥i¤@¥Ø¤FµM, ¤×¨ä¬O²Ä13¶,»¡©úEGFR/Her®a±Ú¥i¤@¦¸³QVarli§í¨î,ªýÂ_©Ò¦³Her®a±Ú¬ÛÃöÀù¤ÆªºSignal Transdution,³oÃIJzªº½T¦³¬ÝÀY...
mops.twse.com.tw/nas/STR/649720171205M001.pdf
¥H¤W¨Ñ°Ñ¦Ò,¤Å·í§ë¸ê¨Ì¾Ú~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/4/18 ¤U¤È 11:33:47
²Ä 115 ½g¦^À³
|
©t¨àÃĤj Ó¤H¥h¦~9¤ë¥ª¥k¶}©l¬ã¨s¨È·à±d¬O·Q§@§ë¸ê²Õ¦X, ÁöµM§ë¤J¸êª÷¤£¦h, ÁöµM«Ü¦h¤H¶]¥ú¥ú, ªO±¦³ÂI§N...... ¨È·à±d´±¥h¬ü°êµo¦æADRªí¥Ü¨ä°]°È°·¥þ, °ê»Ú¤Æªº¥ø¹Ï¤ß°÷, ³o®a¤½¥q³ºµM´±°µ³æÃÄÀø®ÄÁ{§É¸ÕÅç¥YÅã¹ïÃĪ«¾÷¨î¦³«H¤ß,¸Û¦p©t¨àÃĤjª©ÀY¼ÐÃD:°È¹ê¥B¦³¼ç¤Oªº·sÃĤ½¥q , ³o®a¥Ñ¥~¸ê¦¨¥ßªº¥Í§Þ¤½¥q¦p¦ó¦bÀù¯g¬ãµo¹D¸ô¤W¥H¨äÆF¬¡ªºµ¦²¤ ²æĹ¦Ó¥X, ¤j®a´N«ø¥Ø¥H«Ý
¨È·à±d±N¦b¬üÀù¯g¬ã¨s¨ó·|µoªí·s¸ÕÅç¼Æ¾Ú
¨È·à±dªí¥Ü¡AVarliti
2018 ¦~ 4 ¤ë 17 ¤é¡A·s¥[©Y¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d -KY (6497)¤µ¤é«Å¥¬¡A±N¦bªÛ¥[ôÁ|¦æªº 2018 ¦~¬ü°êÀù¯g¬ã¨s¨ó·|(AACR)¦~·|¤Wµoªí varlitinib ªvÀø¨x²ÓMÀù ¤§·s¸ÕÅç¼Æ¾Ú¡C
aslanpharma.com/app/uploads/2018/04/180417_Press-Release_ASLAN-presents-at-AACR-CH.pdf
Ó¤Hµû½×, ¶È¨Ñ°Ñ¦Ò
1¤½¥q2018¦~³W¹º: ( ¨Ì¾Ú2018¦~¤@¤ëªk»¡Â²³ø) GÀù2´Á¸ÕÅç¸ê®Æ¤ÀªR •¤¤°ê²Ä¤G½uÁx¹DÀù¸ÕÅç¸ê®Æ¤ÀªR •²Ä¤@½uÁx¹DÀù2´Á¸ÕÅç¸ê®Æ¤ÀªR •°Ï°ì©Ê¦X§@¥æ©ö®× ASLAN003 •«æ©Ê°©Åè©Ê¥Õ¦å¯f2´Á¸ÕÅç¸ê®Æ¤ÀªR •°Ï°ì©Ê¦X§@¥æ©ö®× ASLAN004 •1´ÁÁ{§É¸ÕÅç¡A§¹¦¨º¦ì¨ü¸ÕªÌ¦¬®× 2019 Varlitinib ¦b¦U¤j¥Dn¥«³õ´£¥XÁx¹DÀùÃÄÃÒ¥Ó½Ð
2¨È·à±d¤w©ó2017 ¦~ 9 ¤ë 7 ¤é±Ò°Ê VARLITINIB ©ó¨x²ÓMÀù(HCC)¤§º¶µÁ{§É¸ÕÅç ( 1b/2 ´Á) ¥¼¨Ó³oÁûÃĦb¬ü°ê¤]¬O»PGÀù¤@¼Ë¬O©t¨àÃÄ ( ¦ý¦b¨È¬w³£¬O¤jÃÄ) 3 ·s¥[©Y°ê¥ß¤j¾Ç¬O¨È¬w±Æ¦W²Ä¤@ªº¤j¾Ç , ·s¥[©Y°ê¤jÀù¯g¤¤¤ß§ó¬O¦W´°ê»Ú
www.nuh.com.sg/wbn/slot/u3917/NUHcorporate_Chinese.pdf
4 ¨È·à±dµu´Á»ùÈÓ¤H»{¬°¬OASLAN 001Áx¹DÀù (¼Ï¯Ã¸ÕÅç)
5 ¨È·à±d¤¤´Áªº»ùÈÓ¤H»{¬°¬OASLAN 001 GÀù( ²Ä¤G/¤T´Á¸ÕÅç ¼Ï¯Ã¸ÕÅç) »P ¨xÀù( 1b/2´Á) , ASLAN 003 «æ©Ê°©ÀH©Ê¥Õ¦å¯f ( ¤w¶i¤J¤G´Á) ¨ÅÀù( ¤G´Á) »P ¤j¸zÀù ( ¤G´Á)
6 ¨È·à±dªø½uªº»ùÈÓ¤H»{¬°¬OASLAN 004 ¹L±Ó®ð³Ý »P ASLAN 001
aslanpharma.com/zh/pipeline/
7 ²Î¤@§ëÅUªñ´Á¦³µû¦ô¨È·à±d¥¼¨ÓASLAN001 Áx¹DÀùÁ`±ÂÅvª÷¹w¦ô°Ï¶¡¡A¦X²zÁ`¥«È¦³«D±`±M·~µû¦ô¡A¦p¯à§â¥i¯à¦b¤G´ÁÁ{§É±ÂÅvªºASLAN003«æ©Ê°©Åè©Ê¥Õ¦å¯f( °Ñ¦Ò2018¦~1¤ëªk»¡·|),(ASLAN004¹L±Ó®ð³Ý»PASLAN001»P¨xÀù¤]¦C¤Jµû¦ô´N§ó§¹³Æ¤F
8 ¦Ü©ó¦ó®É·|±ÂÅv¡AÁ`±ÂÅvª÷¬O¦h¤Ö¡A¦b¨S¦³Â½µP«e¡A¨S¦³¤H·|ª¾¹D¡A±ÂÅvªº¤½§i³£¬O¦b¤j®a·N·Q¤£¨ìªº±¡ªp¤Uµo¥Í¡C
¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/4/18 ¤W¤È 09:39:58
²Ä 114 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j«ü¤F¤@±ø·s»D©ú¸ô~~¨ä¹êADRªºµo¦æÁÙ¬O¦hµ¹¤F¤j¤á¦A¤@¦¸«·sµû»ùªº¾÷·|,¤W¥««eªº»¡©ú·|´X¥G³£¬O¬°¤j¤áªk¤H¾÷ºc©Ò¶}ªº©O~~~¨ì©³¬O¥ý¶R¥x¤W¥h«á°ª½æA©Î¬O¥ý½æ¥x«á§C¶RA¦A©Ô©ïA,³£¦³¥i¯à~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/4/15 ¤U¤È 10:08:28
²Ä 113 ½g¦^À³
|
·j´M¬ÛÃö¸ê°T¥H´£¨Ñ¦Û¤v¿W¥ß§PÂ_¤§°Ñ¦Ò
¨È·à±d¥x·LÅé±Ò°ÊADR±¾µP À禬§Q¦hӪѪí²{¨Î |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/4/9 ¤U¤È 06:55:52
²Ä 112 ½g¦^À³
|
MBE¤j, ¦Ñ·àºCºC¨«¥X¥¦ªº»ùÈ, ¥ý¨«¦V¥«È¦Ê»õÀ³¦³¯q©óADRµo¦æ©w»ù~~¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GMBE10145047 |
µoªí®É¶¡:2018/4/3 ¤W¤È 11:49:03
²Ä 111 ½g¦^À³
|
©t¨àÃĤj, ¥h¦~¬Ý±z¶}ª©«á,¶}©l¬ã¨s³o®a¤½¥q ·sÃĪѤ¤¸Î¤w¨úÃÒ,ÃĵØÃÄ¥u³Ñ®É¶¡°ÝÃD ¥¼¨ÓÓ¤H¬Ý¦n¨È·à±d¤Î¥_·¥¬P¦¨¥\¾÷²v¸û°ª ÁöµM¥Ø«e¤wµL«ùªÑ,¤´·PÁ±zªø´Áªº°lÂܤΤÀ¨É
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/3/31 ¤U¤È 03:25:10
²Ä 110 ½g¦^À³
|
¦Ñ·à°e¥óADRµo¦æ~~¦Ü¤Ö±N´`¥x·LÅé¼Ò¦¡±NªÑ»ù«O«ù¦b¬Û¹ï°ªÀÉ°Ï,¥H§QADR»ù®æµo¦æ»ù~~
news.cnyes.com/news/id/4078474
¥H¤W¨Ñ°Ñ¦Ò~~¤Å¥Î¥HªÑ²¼§ë¸ê¶i¥X¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤Ñ®¦10141363 |
µoªí®É¶¡:2018/3/16 ¤U¤È 05:38:45
²Ä 109 ½g¦^À³
|
³o¤@¤ë ¨C¤Ñ¥á³æ¤l ¬å»ù ³Í°òÁ`¤½¥q ½æ¶W 1429 ±i
³o»òÄꪺ6497 ³Í°òÁÙ·íµo¦æ¨é°Ó www.wantgoo.com/stock/astock/agentstat?stockno=6497&type=3.5
ª÷ºÞ·|¤£ºÞ¶Ü ¤S¬O¶BÄF¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/3/14 ¤W¤È 12:30:05
²Ä 108 ½g¦^À³
|
²Î¤@§ëÅU¬ã¨sû2018²Ä¤@©u¦³Ãö¨È·à±d¦X²z»ùÈ¡A¥¼¨ÓASLAN001Á`±ÂÅvª÷¹w¦ô°Ï¶¡¡A¦X²zÁ`¥«È¦³«D±`¸Ô²Óµû¦ô¡C³o¥÷¬ã¨s³ø§i¼gªº«D±`±M·~¡A¦ý¨Ã¨S¦³§â¦b¤G´ÁÁ{§ÉªºASLAN003«æ©Ê°©Åè©Ê¥Õ¦å¯f¹w¦ô±ÂÅvª÷¦C¤Jµû¦ô¡C ¦Ü©ó¦ó®É·|±ÂÅv¡AÁ`±ÂÅvª÷¬O¦h¤Ö¡A¦b¨S¦³Â½µP«e¡A¨S¦³¤H·|ª¾¹D¡A±ÂÅvªº¤½§i³£¬O¦b¤j®a·N·Q¤£¨ìªº±¡ªp¤Uµo¥Í¡C¥H¤WÓ¤H¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/3/12 ¤W¤È 12:09:33
²Ä 107 ½g¦^À³
|
¤¤°êÁx¹DÀù¥«³õ¤£®e©¿µø:¥H¤U¸ê°T¶È¨Ñ°Ñ¦Ò¡C ¨È·à±d¤w¦b¤¤°ê±Ò°Êvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¼Ï¯Ã¡B³æÁu¡B¦h¸ÕÅ礤¤ß¤§Á{§É¸ÕÅç¡A¨ü¸Õ¹ï¶H¬°¤w¦Ü¤Ö±µ¨ü¤@½u¥þ¨©ÊªvÀø¤§±ß´Á©ÎÂಾ©ÊÁx¹DÀù¯f±w¡C¦@¦¬68¦ì¨ü¸Õ¡A¥DnÀø®Ä«ü¼Ð¬OORR¡C¹wp±N©ó2018¦~©³³ø§i¸ÕÅç¼Æ¾Ú¡AY¹F¼Ð±N¥i±æ»â¥ý쥻ªº³W¹º®Éµ{¤@¦~¦VCFDA°e¥Xº¦¸²Ä¤G½uÁx¹DÀù·sÃĵù¥Uµn°O¥Ó½Ð¡A¤¤°êÁx¹DÀù¤H¼Æ¹w¦ô14.5¸U¤H¡A¥«³õ¤£®e©¿µø |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/3/9 ¤U¤È 03:09:03
²Ä 106 ½g¦^À³
|
°ê¤º²ÎX§ëÅU¤½¥q©ó¤¤¸Î¨ú±oÃÄÃÒ«á,µoªí°ê¤º·sÃIJ£·~µûªR,¦Ó¹w´Á¦Ñ·à±N©ó¤C¤ëµo¦æADR¤ÎALSAN003²Ä¤T©u¦³±æ°ê»Ú±ÂÅv~~
¥H¤W¨Ñ°Ñ¦Ò.. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/3/7 ¤W¤È 09:07:04
²Ä 105 ½g¦^À³
|
©t¨àÃĪºq»ùªGµM¤£¤@¼Ë¡A¨È·à±d¨«¦b¹ïªº¸ô¤W¡AºX¤UGÀùÁx¹DÀù¤wÀò±o¬ü°êFDA©t¨àÃÄ»{©w¨ÃÂùÂù¶i¤J¼Ï§á¸ÕÅç
®¥¶P¤¤¸Î·sÃĤ½¥q,§ë¸ê¤H»P ªø´Á§ë¤J¬ã¨sªº¬ì¾Ç®a»P¬ãµo¤Hû
¤¤¸Î¥ý«e«e¤wÀò±o¬ü°êFDA®Öã³q¹LÀ³¥Î©ó¦h«§ÜÃĩʯf¤H©t¨àÃĸê®æ¡A¨Ã³°ÄòÀò±o¬ð¯}©ÊªvÀø»PÀu¥ý¼f¬d¸ê®æ¡A¥»¤ë6¤éTMB-355Àò±o¬ü°êFDA¥Íª«»s¾¯ÃÄ«~¤W¥«¬dÅçµn°O®Öã¡AÃÄ»ùq¬°¨C¤H¨C¦~¬üª÷11.8¸U¬ü¤¸¡A°ª©ó¥ý«e¥«³õ¹w¦ôªº5¸U¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/2/19 ¤W¤È 11:33:07
²Ä 104 ½g¦^À³
|
¹Dã¦^Àɤ£¬O¬ü°ê¸gÀÙÂà®z¡A¦Ó¬O«D²z©Êªº³q¿±¾á¼~ ¥xªÑ«ÊÃö¨ì2¤ë16¤é ¬ü°ê¹Dã¤wº¦¶W¹L¤dÂI 24190.90 >>>>> 25219.38 (º¦1028.48ÂI)
6497 ¥~¸ê¶R½æ¤ë³øªí 2018¦~2¤ë ¶R¶W4703±i ½æ¶W1919±i ¶R½æ¶W2784±i (²Îp¨ì 2018¦~2¤ë 12¤é)
2018¦~1¤ë ¶R¶W1281±i ½æ¶W66±i ¶R½æ¶W1215±i 1 ¦Ü 2¤ë12¤é ¶R¶W3999 ±i
¥H¤W¸ê°T¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å°µ¬°§ë¸ê¤§¨Ì¾Ú¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¦t10145840 |
µoªí®É¶¡:2018/2/12 ¤U¤È 06:18:44
²Ä 103 ½g¦^À³
|
³o¨â¤Ñ¥Dn¬O¬üªL¦b½æ¡A¬üªL¥»¨³£¬O°µµu½u¡Aµu´Á¤º¤£ºÞªÑ»ù¦h¤Ö³£·|½æ¥X¡Aªø½u«ù¦³ªº¤£¥ÎºÞ¥Lªº¾Þ§@¡A¨ä¥L´N¬O«e´X¤Ñ¶Rªº¦³¨Ç¤£·Q³øªÑ¹L¦~ªº½æÀ£¡A¤µ¤ÑÁöµM¥´¨ì¶^°±¦ýÁÙ¬O¦³¤H¦b©Ó±µ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2018/2/12 ¤U¤È 02:56:36
²Ä 102 ½g¦^À³
|
¤£ª¾¬°¦ó³o¨â¤ÑªÑ»ù×¥¿¤£¤Ö¡A¥HÄw½X¨Ó¬Ý¦³¨Ç¬O§«ô¥|°lº¦°±ªº¡AµM«á§«ô¤¦]¬°¬üªÑ¤j¶^±þ¥X¡A¦³¨Ç¥i¯àµu½uÀò§Q¤Fµ²¡A¬Y¨Ç¤jªÑªFÁÙ¬O¤Î«ùÄò½æ¥X¡A¦~«eªº½æÀ£ÁÙ¯uªºÆZ®£©Æ¡AÅý¨È·à±dª½±µ¶^¯}5¤é½u¡A¬Ý¨Ón¾ã²z¤@¬q®É¶¡¤F¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/2/12 ¤W¤È 12:17:19
²Ä 101 ½g¦^À³
|
©t¨àÃĤj ¨È·à±d¬O«Ü¦³¼ç¤Oªº§ë¸ê²Õ¦X¼Ðªº¡AASLAN001Áx¹DÀù¡AGÀù¬O©t¨àÃÄ¡AASLAN003¾AÀ³¯g¬OAML«Ü¦³¼ç¤O¡AASLAN004¹L±Ó®ð³ÝÃÄ¥«³õ¤j¡A³o®a¤½¥q·í¤j®a©¿µø¥Lªº¦s¦b®É¤w¸g¦b¤£ª¾¤£Ä±¤¤³Q¥~¸ê¬Ý¤¤¡A¤j®a¤@°_¥[ªo¡C¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò¡A½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p°¨10135228 |
µoªí®É¶¡:2018/2/9 ¤W¤È 11:07:47
²Ä 100 ½g¦^À³
|
Ãĵؽ¬õ¤jº¦¤F ©Î³\éw·àµ¥¤@¤U¤]¦³¾÷·| ¦b³oÓ¸`°©²´¡An¹³ÃĵؤΨȷà³oºØ¦³§Y´Á«¤j§Q¦hªÌ¤~·|¨ü·ú·ý |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/2/9 ¤W¤È 10:36:45
²Ä 99 ½g¦^À³
|
¥xÁÞ¤j, ¤]·PÁ§A±`±`¤À¨É«D±`¦³¥Îªº°T®§~~¤½¥q¸Ó°µªº³£°µ¤F,±µ¤U¨Ó´N¬OÁ{§É¼Æ¾Ú,ADRq»ù¤Îµo¦æ®ÉÂIªº°ÝÃD¤F~~Y¥H¬ü°ê´îµ|¤Î¶Å¥«¶]¥X¨Óªº¸êª÷¨Ó¬Ý, ¦³¼ç¤Oªº·à¤lÀ³¸Ó«Ü¦³¾÷·|³Q«C·ý...
¥H¤W¨Ñ°Ñ¦Ò~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/2/8 ¤U¤È 11:01:16
²Ä 98 ½g¦^À³
|
¦Ñ´¤j ·à¤Í³£«Ü·PÁ¦Ѵ¤jµL¨p´£¨ÑÂå¾Ç±M·~¤À¨É,¥u¯à¥Î¹d²ÓÃû¿ò¨Ó§Î®e. ¬Û«H¦³¥»½èªº¥Í§Þ¤½¥q³£·|¦³ªí²{ªº¾÷·|,¢±¢¯¢°¢·¡@¥xÆW¥Í§Þ¥[ªo¡@¤j®a¥[ªo¡I¡@ª¯¨Ó´I¡@¡I¡@¡@ ¡@¡@
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/2/8 ¤U¤È 10:38:36
²Ä 97 ½g¦^À³
|
¦Û±q·à¤l2018¦~1¤ë10¤é¨ì¬ü°êª÷¤s°Ñ©ó¼¯®Ú¤j³qÁ|¿ì¤§²Ä36©¡ÂåÀø«O°·¦~·|µoªí¤½¥q²³ø«á¥~¸ê¶R¶W±¡ªp 2018¦~ 1¤ë ¶R¶W 1215 ±i 2018¦~ 2¤ë ¶R¶W 3153 ±i ( ²Îp¨ì2¤ë8¤é¤î ) 1¤ë+ 2¤ë1¤é-2¤ë8¤é Á`¦@¶R¶W4368 ±i ¶R¶Wì¦]¤£©ú?¡@¡]Äw½X¶V§l¶V°®²b¡I¡^
·s¥[©Y¨Ó¥x±¾µPªº¥Í§Þ¤½¥q6497°÷®ð¾z , ª½±µ¨ì¬ü°êµo¦æADR ¤£¸ò§ë¸ê¤H®³¿úÁÙ°eµ¹ªÑªF¤j¬õ¥]¡I¡@
¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p°¨10135228 |
µoªí®É¶¡:2018/2/8 ¤U¤È 09:23:28
²Ä 96 ½g¦^À³
|
¨È·à±d-KY(6497)±NµoADR¡A¥~¸ê¥ý¥d¦ì¡AGÀù·sÃĪì¨B¼Æ¾Ú¤µ¦~´¦¾å ¡i°]°T§Ö³ø¡þ¦ó¬ü¦p³ø¾É¡j¨È·à±d-KY(6497)¶}µo¤¤·sÃÄvarlitinib©óÁx¹DÀù¡BGÀù¡B¨ÅÀù»P¤j¸zª½¸zÀù¤§Á{§É¼Æ¾Ú¥¿±¡A¥«³õ´Á«Ý¥Î©óªvÀø±ß´Á©ÎÂಾ©ÊGÀù¤§¥þ²y¤G/¤T´Á¸ÕÅç¡Aªì¨B¼Æ¾Ú¹wp2018¦~´¦ÅS¡A¤½¥q¤é«e¤w¤j¤âµ§¶R¦^¥þ²y°Ó«~¤ÆÅv§Q¡A¨Ã³W¹º¤µ¦~¦b¬ü°êµo¦æADR(¬ü°ê¦s°U¾ÌÃÒ)¡A¥«³õ°¾¦h¬Ý«Ý¡A¥~¸ê¤]¿n·¥¥d¦ì¡Aµuµu7Ó¥æ©ö¤é¤w¶R¶W2400±i¡A¿EÀyªÑ»ù½Ä¤W53.5¤¸³Ð8Ó¤ë·s°ª¡C ¨È·à±d¾Ö¦³¤¶µÔ¿ïÃĪ«¤Î¤@ÓModybodies¥¥x¡A¥DnÃĪ«varlitinib (ASLAN001)¬ãµo¤¤¤§¾AÀ³¯g¥]¬AÁx¹DÀù¡BGÀù¡BÂಾ©Ê¨ÅÀù»PÂಾ©Ê¤j¸zª½¸zÀù¡CVarlitinib¤é«e¤w¨ú±o¬ü°êFDA®Öã®i¶}Áx¹DÀù¥þ²y¤G´Á/¤T´Á¼Ï¯ÃÁ{§É¸ÕÅç¡A¹wp¥¼¨Ó2-3¦~§¹¦¨¡C ¦Ó¥~¬ÉÃöª`ªºvarlitinib©ó²Ä¤@½u(HER1/ HER2¦@¦Pªí²{)±ß´Á©ÎÂಾ©ÊGÀù¤§¥þ²y¤G/¤T´Á¸ÕÅç¡A¥h¦~¤w¶}©l¦¬®×¡A¦Xp±N©Û¦¬¬ù40¦ìHER1/ HER2¦@¦Pªí²{¥B¥ý«e¥¼±µ¨ü¹L¥þ¨©ÊªvÀøªº¯f±w¡Aªì¨B¼Æ¾Ú¹wp2018¦~´¦ÅS¡A¤T´ÁÁ{§É«h¹wp©ó¥¼¨Ó4-5¦~§¹¦¨¡CGÀù¬O¨È¬w²Ä¤G¤jÀù¡A¬ü¤¤¤éÁú¨C¦~¦º¤`¼Æ64.5¸U¤H¡A¥«³õ¹ï¥¼¨Óµo®i±H¤©«p±æ¡C varlitinib©óÂಾ©Ê¨ÅÀù¤§¾AÀ³¯g¶i«×¬°¤w§¹¦¨²Ä2a´ÁÁ{§É¸ÕÅç¡A¸Ó¸ÕÅçÂê©wHerceptinªvÀø¥¢±ÑªºHER2ÂX¼W¯f±w¡A´Á¤¤¤ÀªR¸ê®ÆÅã¥Ü¡Avarlitinib¹ï¯f±w²£¥Í·¥¨Î¤§Àø®Ä¡A¥B@¨ü©Ê¤Î¦w¥þ©Ê¨}¦n¡C ¬°´x´¤¦Û¦æ±NÃĪ«±a¤J¥«³õ¨Ã¦b¯S©w¦a°Ï°Ó«~¤ÆÅv§Q¡A¨È·à±d¤é«e¤w«Å¥¬¡A±qArray BioPharma¨ú±o¥þ²y¶}µo¡B»s³y»P°Ó«~¤Ævarlitinib¤§©Ò¦³Åv¡Añ¬ùª÷»P¨½µ{¦Xp¤£¶W¹L1.29»õ¬ü¤¸¡A¥¼¨Ó¾P°âÅv§Qª÷¤£¶W¹L§CÂù¦ì¼Æ¡C ¨È·à±d¤é«e«Å¥¬¡A±N¦b¬ü°êµo¦æADR¡Aªñ¤é¤w¨ú±oª÷¿ÄºÊ·þºÞ²z©eû·|ª÷ºÞÃÒµo¦r²Ä1060049975¸¹®Öã¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡A¹wp¶Ò¸ê4852¸U¬ü¤¸¡A§é¦X·s¥x¹ô¬Ò¬ù14»õ¤¸¡A¥~¬É¹w´Á¡A¤µ¦~´N·|µo¦æ¡A¨Ã¦³§U»P°ê»Ú±µy¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GLin10142144 |
µoªí®É¶¡:2018/2/8 ¤U¤È 04:18:57
²Ä 95 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p°¨10135228 |
µoªí®É¶¡:2018/2/7 ¤W¤È 09:20:46
²Ä 94 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p°¨10135228 |
µoªí®É¶¡:2018/2/7 ¤W¤È 08:26:30
²Ä 93 ½g¦^À³
|
¥~¸ê¬Q¤Ñ³{§C¤S±½¤F500¦h±i ·s»D»¡¤½¥q¤µ¦~nu¬üµo¦æADR ªüÁø»¡¦³¤@ÀɧC»ù¥Í§ÞªÑnº¦¤@¿¬Oéw·à¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GLin10142144 |
µoªí®É¶¡:2018/2/1 ¤U¤È 03:36:42
²Ä 92 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/2/1 ¤W¤È 08:42:15
²Ä 91 ½g¦^À³
|
Lin ¤j ¨È·à±d¤½¥qºô¯¸³Ì·s®ø®§¡G¡@¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·|
aslanpharma.com/zh/2018/01/31/aslan-pharmaceuticals-sponsors-cholangiocarcinoma-foundation-annual-conference-2018/
¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·| 2018 ¦~ 1 ¤ë 31 ¤é¡A·s¥[©Y¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½ ¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬±N¾á¥ô 2018 ¦~ÁxºÞÀù°òª÷·|¦~·|¤§¾ó¾ð¯ÅÃÙ§U°Ó(Oak sponsor)¡A¦¹·|ij ±N©ó¬ü°êµS¥L¦{ÆQ´ò«°Á|¦æ¡C ¥ÑÁxºÞÀù°òª÷·|Äw¿ì¤§¦~·|±N©ó 2018 ¦~ 1 ¤ë 31 ¤é¦Ü 2 ¤ë 2 ¤éÁ|¦æ¡AÁܽЬã¨s¤Hû¡BÂåÀø«O°·±M·~ ¤H¤h¡B¬Fµ¦¨î©wªÌ¡B¯f±w¤Î·ÓÅ@ªÌ»ô»E¤@°ó¡A³z¹L¦¹¦¸ª¾ÃÑ»P³Ð·s¥æ¬y¤§½×¾Â¡A«P¶iÂå¬É»P¾Ç¬É±´ ¨sÁxºÞÀù¬ÛÃöijÃD¡C ¨È·à±d-KY ±N¦b¥»¦¸·|ij¤¤°w¹ï TreeTopp ¸ÕÅç³]p(Treatment Opportunty)µoªí²³ø¡CTreeTopp ¬°¤@ ¶µ¥¿¦b¶i¦æ¤¤¤§¥þ²y¼Ï¯ÃÁ{§É¸ÕÅç¡A¥Øªº¬°±´°Q¨È·à±d-KY ¥DnÔ¿ïÃĪ« varlitinib ©óÁx¹DÀù¤§Àø ®Ä¡C¥»¦¸Â²³ø±N¤£·|µoªí·sªº¬ã¨s¼Æ¾Ú¡CVarlitinib ¤wÀò±o¬ü°ê¹«~ÃĪ«ºÞ²z§½(US FDA)Áx¹DÀù¨È«¬¢w ÁxºÞÀù¤§©t¨àÃĸê®æ»{©w¡C ¨È·à±d-KY Âå¾Çªø Bertil Lindmark ³Õ¤hªí¥Ü¡G¡uų©ó¥Ø«e¦bÁxºÞÀù»P¨ä¥L§Î¦¡¤§Áx¹DÀù©|µL®Ö㤧Àø ªk¡A³oÃþ¯e¯f¢¤Á»Ýn¦³®ÄÀøªkªº¬ãµo¥H¦]À³¥þ²y¤§ÂåÀø»Ý¨D¡C¨È·à±d-KY «Üºa©¯¯à°Ñ»P¤ä«ù³o¶µ« nªº·|ij¡AÅýÂåÀø¬ÉÂǦ¹¾÷·|¯à°÷°w¹ï¯f±w¤ä«ù·ÓÅ@¡B¯e¯f»{ª¾«Ø¥ß¤Î·sªvÀø¿ï¾Üµo®iµ¥±¦V¶i¦æ ¥æ¬y¡C¡v
Ó¤H¤À¨É ¢°³Ìªñ¥~¸êªº½T¤@ª½¶Rì¦]¤£©ú? ³o¤w¤Þ°_¤j®aª`·N!¨È·à±dªº¥~¸êªø´Á§ë¸ê©~¦h,¤£¥²²z·|§ëÅUµu´Á¾Þ§@
¢±¨È·à±d±NÃÙ§U 2018 ¦~ÁxºÞÀù°òª÷·|¦~·|¥Øªº¬O§i¶D¬ü°ê¯f±wVarlitinib¥þ²y¼Ï¯ÃÁ{§É³]p,§ÜÀù¾÷¨î, (US FDA)Áx¹DÀù©t¨àÃĸê®æ»{©w¡C¥Ø´ÁªvÀøª¬ªp, ·¾³q»¡©ú¥H¤è«K¯f±w©Û¶Ò¨Ã¬°¥¼¨ÓÃĪ«¤W¥«¥´ª¾¦W«×¡^
¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GLin10142144 |
µoªí®É¶¡:2018/1/31 ¤U¤È 11:27:36
²Ä 90 ½g¦^À³
|
ÁÞ®v¡G¤µ¤Ñ±çºÑÁøªüÀ¨¡D¥s¤H§â·à¤l¥þ±þ¥ú¤F¡A ©_©Ç¥~¸ê¤@ª½¥[½X¡D§ÖÅܦ¨¥~¸ê¤½¥q¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2018/1/30 ¤U¤È 10:06:53
²Ä 89 ½g¦^À³
|
³oӨȷà±d©xºô¤½§iªº¸ê°T¤ñ¸û§¹¾ã
2018¦~1¤ë8¤é¡A·s¥[©Y ¡V±Mª`©ó¶}µo¨È¬w²±¦æ»P¼Ú¬ü©t¨à¯e¯fÀù¯g¡B¦ì©óÁ{§É¶¥¬q¤§¥Íª«»sÃĤ½¥q¨È·à±d-KY (6497)¤µ¤é«Å¥¬¡A¦bªñ´Á»PCFDA(¤¤°ê°ê®a¹«~ÃĪ«ºÞ²zÁ`§½)§¹¦¨varlitinibÁx¹DÀùÁ{§É¸ÕÅçµo®iµ¦²¤¤§°Q½×«á¡AY¸g®Öã¡Avarlitinib¦b¤¤°ê°Ó«~¤Æ¤§¶i«×±N¥i±æ¸û¹w´Á´£¦¤@¦~¡C
¨È·à±d-KY°õ¦æªø³Å«i³Õ¤hªí¥Ü¡G¡u¤¤°êªñ´Áªk³Wªº§ïÅÜ¥Nªí¤F°w¹ï¦pÁx¹DÀùµ¥¥¼³Qº¡¨¬¥«³õªº·sÃĵo®i±N¥i±æ¥[³t¡A³o±N¨Ï¨È·à±d-KY¦³¾÷·|¥i¥H§ó§Ö¦a¬°¶È¦³¤Ö¼ÆªvÀø¿ï¾Ü¤§¯f±w±a¨Ó·s¿o¥B«nªºªvÀø¿ï¶µ¡C¨È·à±d-KY¤w©óªñ´Á¨ú±ovarlitinib¥þ²y¶}µo»P°Ó«~¤Æ¤§©Ò¦³Åv¡A§Ú̲{¥¿µÛ¤â¥´³y¦b¤¤°êªº¹Î¶¤¡A¬°varlitinibªº¤W¥«°µ·Ç³Æ¡C¡v
¨È·à±d-KY¤w©ó2017¦~¦b¤¤°ê±Ò°Êvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¼Ï¯Ã¡B³æÁu¡B¦h¸ÕÅ礤¤ß¤§Á{§É¸ÕÅç¡A¨ü¸Õ¹ï¶H¬°¤w¦Ü¤Ö±µ¨ü¤@½u¥þ¨©ÊªvÀø¤§±ß´Á©ÎÂಾ©ÊÁx¹DÀù¯f±w¡C¦¹¸ÕÅç¥Ñ¾á¥ô¤¤°êÁ{§É¸~½FÂå¾Ç·|¥D®u¡B¸Ñ©ñx«n¨Ê¤K¤@Âå°|°Æ°|ªøªº¯³¨û¶f±Ð±Â¥D¾É¡C
¸Ó¸ÕÅç±Nµû¦ô¦@68¦ì¨ü¸Õ¯f±w¦bvarlitinib»Pcapecitabine¦X¨Ö¨Ï¥Îªº¦w¥þ©Ê»P@¨ü©Ê¡A²{¤w±Ò°Ê¨ü¸Õ¯f±w©Û¦¬§@·~¡A¨ä¥Dn¸ÕÅç¥Ø¼Ð¬°«ÈÆ[¤ÏÀ³²v(ORR)¡C¨È·à±d-KY¹wp±N©ó2018¦~©³³ø§i¸ÕÅç¼Æ¾Ú(top-line data)¡AY¥Dn¸ÕÅç¥Ø¼Ð¹F¨ì¹w´Á¡A±N¥i±æ»â¥ý쥻ªº³W¹º®Éµ{¡A´£¦¦VCFDA°e¥Xº¦¸²Ä¤G½uÁx¹DÀù·sÃĵù¥Uµn°O¤§¥Ó½Ð¡C
¨È·à±d-KY¤w»P¤¤°ê¤§¥Í²£¹Ù¦ñ±K¤Á¦X§@¡AÂù¤è¤w¦b¤µ¦~ªì¨î©w²Å¦XGMP¼Ð·Ç¤§¥Í²£¬yµ{¡C¤½¥q¹w´Ávarlitinib¤§¥Í²£¨ÑÀ³Ãì±N¦b2018¡B2019¦~´N¦ì¡A¥H¤äÀ³·sÃĵù¥Uµn°O»P¤§«á¤§¤W¥«»Ý¨D¡C
¨Æ¹ê¤W¡A¨C¦~¦b¨È¬w·s¼W¤§Áx¹DÀù¯f¨Ò¬ù¦³20¸U¨Ò¡A¨ä¤¤¤¤°ê´N¦û¤F14.5¸U¡F¦Ó¦b³Qµø¬°¬O©t¨à¾AÀ³¯gªº¬ü°ê¡A¨C¦~«h¬ù¦³1.26¸U¤§·s¼WÁx¹DÀù¯f¨Ò¡C¥Ø«eÁx¹DÀù¦b¤¤°ê»P¬ü°ê¬Ò©|µL³Q®Ö㤧Àøªk¡C
Ó¤H¤À¨É: 1¨C¦~¦b¨È¬w·s¼W¤§Áx¹DÀù¯f¨Ò¬ù¦³20¸U¨Ò¡A¨ä¤¤¤¤°ê´N¦û¤F14.5¸U ¥«³õ¤£®e¤p觑 2±À¦ô¤¤°êÁx¹DÀù¤W¥«®É¶¡¬ù¦b2020¦~ 3±À¦ô¤¤°ê»P¬ü°ê¤W¥«®É¶¡«D±`±µªñ
¥H¤WÓ¤H¤À¨É±À´ú¬O¨Ì¾ÚA B
A ¥h¦~12¤ë®ü¥~ªk»¡·|²³ø, 2019 ¦~ Varlitinib¦b¦U¤j¥Dn¥«³õ´£¥XÁx¹DÀùÃÄÃҥӽРB 2018¦~1¤ë8¤é©xºô³Ì·s®ø®§: ¤½¥q¹w´Ávarlitinib¤§¥Í²£¨ÑÀ³Ãì±N¦b2018¡B2019¦~´N¦ì »P¤¤°êÁx¹DÀù¤H¼Æ
¥H¤W¤À¨É¶È¨Ñ°Ñ¦Ò,½Ð¤Å·í¬°§ë¸ê¤§¨Ì¾Ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/1/18 ¤W¤È 09:50:12
²Ä 88 ½g¦^À³
|
¤ñ¸û°ê¤º³\¦h·sÃĤ½¥q¨È·à±d¨úÃÒªº®Éµ{¹w¦ô¦¤F³\¦h,¦b³oÃÄ¿z¥¥x¶V¨Ó¶V¼F®`ªº¤j¼Æ¾Ú®É¥N,¥ý°w¹ï©t¨àÃĽdÃ¥ºÉ³t®³¨ìÃÄÃÒ¤~¬O¨È¬w·sÃĤ½¥qªº§Q°ò~~~
1.¨È·à±d¤j³°ÁxºÞÀùªº¶µ¥Ø~~¦³±æ´£¦¤@¦~,³sµ²¦p¤U: www.chinatimes.com/realtimenews/20180108003886-260410
2.³Ì·sªk»¡·|¸ê®Æ(»P¥ý«e¬Û¦P,¶È¦³°Ï°ì±ÂÅv®×©Ôªø¦Ü¥þ¦~¹ê²{)
¥H¤W¨Ñ°Ñ¦Ò, §ë¸ê¦Ût¬ÕÁ«~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/1/8 ¤U¤È 04:20:03
²Ä 87 ½g¦^À³
|
¨È·à±d¤j³°ÁxºÞÀùªº¶µ¥Ø~~¦³±æ´£¦¤@¦~,³sµ²¦p¤U:
www.chinatimes.com/realtimenews/20180108003886-260410
¥H¤W¨Ñ°Ñ¦Ò, §ë¸ê¦Ût¬ÕÁ«~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2018/1/4 ¤W¤È 08:44:46
²Ä 86 ½g¦^À³
|
¸òarray½Í¦n±ÂÅv¤Î¨½µ{«á,´N¯àµL«áÅUªº¥h½Í¤U´å¾P°â±ÂÅv¤F~~~´Nµ¥¤U´å±ÂÅv¤Î´Á¤¤¼Æ¾Ú¤F~~¥[ªo¦Ñ·à |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2017/12/14 ¤U¤È 07:49:10
²Ä 85 ½g¦^À³
|
¥ÃÂת÷«n¨Ê¤µ¤é«ùÄò˳f ¦ý¥«³õ¤]¦³¤H¤£Â_§C±µ ÁÙ¦n°Õ!³{§CºCºC±µ¡A¨Ó¤ñ½Ö®ðªø |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2017/12/13 ¤U¤È 04:09:39
²Ä 84 ½g¦^À³
|
ÁöµM³Í°òÁ`¤½¥q¨S¦b½æªÑ¡A¤£¹L¤µ¤Ñ¤S¶]¤@®a¥ÃÂת÷«n¨ÊˤF176±i¥X¨Ó¡AªÑ»ùª½±µ¤U±þ¨ì32¡A¤£ª¾¤½¥q¬£¯à®³¥X¤°»ò¤èªkÅýªÑ»ù¤î¶^©O? µo¦æADR¸ò®ü¥~±ÂÅv³£ÁÙ¨S¨º»ò§Ö¥i¥H¦³µ²ªG¡A¦ý¬OªÑ»ù¦b¨SÔ£§QªÅ¤§¤U¤@¸ô©¹¤U±´¡A¤£ª¾¹D¦ó®É¤~¯à¤î¶^¦^¤É©O? |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 6501 ~ 6600 «h¦^ÂÐ >> |